Treatment-resistant depression complicates care, defying standard treatments, but new therapies are on the horizon, offering hope for more effective treatment options.

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...

Ketamine is often viewed more as a party drug than a medicine. One Columbia clinic is using the drug to help patients with ...

Psychedelics have been recreational substances for decades. Now, they're entering the mainstream of psychiatric treatment.

Ketamine, a non-competitive N-methyl-D-aspartate receptor antagonist, has emerged as an effective therapeutic agent for the management of treatment-resistant depression. Repeated treatments with ...

Faster-acting drugs have long been sought to protect people with severe depression who may be at risk of self-harm or suicide ...

NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

Major depressive disorder (MDD) is a leading cause of disability worldwide, with a significant proportion of patients (10-20%) progressing to treatment-resistant depression (TRD).

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase 2b study of SPN-820 in adults with ...

The government is preparing to fund the use of MDMA and psylocibin, otherwise known as ecstasy and magic mushrooms, as a ...

St John of God Hospital in Dublin has said it is the first hospital in Ireland to introduce a special treatment for patients ...

Supernus Pharmaceuticals may have had a potential path forward for its depression drug candidate cut off after the asset ...